Mp73-08 intravesical Gemcitabine and Docetaxol in Heavily Pre-Treated Patients With Non-Muscle Invasive Bladder Cancer (Nmibc)

Caruso, Adele M.; Ravishankar, Roshan; VanArsdalen, Keith; Malkowicz, S. Bruce

doi:10.1097/ju.0000000000000959.08

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cox regression analysis revealed the perseverance of carcinoma in situ (CIS), and the number of prior BCG unresponsive patients was not significantly associated with disease recurrence [5 ▪▪ ]. In a similar patient population, Caruso et al [18] reported an objective response rate at first surveillance of 92% and a mean RFS of 12.5 months. We performed proportional meta-analyses for HG-RFS and the rate of patients who required radical cystectomy in two studies [5 ▪▪ ,20].…”

Section: Resultsmentioning

confidence: 99%

“…Our initial search led to the identification of 1224 publications; after exclusion of duplicates, 763 were screened; then, 749 publications were excluded during the title and abstracts review process. According to inclusion criteria, six studies comprising 527 patients were included [5 ▪▪ ,17,18,19 ▪▪ ,20,21]. The PRISMA flowchart is presented in Supplementary Figure 2, http://links.lww.com/COU/A41.…”

Section: Resultsmentioning

confidence: 99%

“…Three studies [5 ▪▪ ,18,20] assessed the oncologic outcomes in the BCG unresponsive setting. The largest multicentre study by Steinberg et al [5 ▪▪ ] evaluated intravesical GEM/DOCE therapy as rescue therapy for NMIBC patients with a history of BCG instillation therapy.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis

Kawada

Yanagisawa

Araki

et al. 2022

Current Opinion in Urology

View full text Add to dashboard Cite

Purpose of reviewShortages in intravesical Bacillus Calmette-Guérin (BCG) immunotherapy represent a challenge in the management of high-risk nonmuscle invasive bladder cancer (HR-NMIBC). This study aimed to review the efficacy and safety of intravesical gemcitabine (GEM) and docetaxel (DOCE) for BCG-naive and unresponsive HR-NMIBC.Recent findingsWe identified six studies eligible for quantitative analysis through a systematic search according to the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) statement. In the two studies in the BCG-naive setting, 1-year and 2-year pooled recurrence-free survival (RFS) were 86 and 84%, respectively. In the two studies in the BCG unresponsive setting, 6-month, 1-year and 2-year pooled high-grade recurrence-free survival (HG-RFS) were 80, 66 and 51%, respectively. Cumulative data from four studies revealed that 2.3% of patients could not complete induction therapy and 6.9% experienced treatment delay or dose reduction due to adverse events.SummaryDespite the preliminary data and based on a small sample size, intravesical GEM/DOCE therapy is a highly promising combination yielding an effective and well tolerated alternative to BCG when indicated. Further large, well designed comparative studies with BCG are needed.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis

Kawada

Yanagisawa

Araki

et al. 2022

Current Opinion in Urology

View full text Add to dashboard Cite

show abstract

“…У 16 из 26 пациентов был выявлен рецидив в среднем через 12,45 (3-24) мес, у 10 больных отсутствовали признаки рецидива в среднем в течение 9,6 (3-15) мес. Отмечена удовлетворительная переносимость [4]. Режим также может быть использован в случае отказа от цистэктомии (ЦЭ).…”

unclassified

Bladder cancer: what’s new in 2019—2020

Карякин

2021

Onkourologiâ

View full text Add to dashboard Cite

В обзоре представлены новые данные по лечению больных раком мочевого пузыря за указанный период. Большинство из них опубликовано на основании результатов рандомизированных исследований и имеет доказательный характер. На консенсусном митинге патоморфологов предложена новая классификация с учетом молекулярно-генетических данных. Показана четкая зависимость продолжительности жизни от морфологического строения опухоли. Представлены схемы химиотерапии в случае непереносимости вакцины БЦЖ (бациллы Кальмета-Герена). Иммунотерапевтические препараты для лечения мышечно-инвазивного рака мочевого пузыря все больше изучаются, и идет поиск последовательности их комбинаций с другими противоопухолевыми препаратами. Европейскими урологами предложена новая классификация побочных явлений, связанных с оперативными вмешательствами. Даны рекомендации по проведению лекарственного и хирургического лечения больных раком мочевого пузыря в период пандемии COVID-19. В заключении представлены мнения экспертов консенсусного митинга по лечению различных форм рака мочевого пузыря.

show abstract

Mp73-08 intravesical Gemcitabine and Docetaxol in Heavily Pre-Treated Patients With Non-Muscle Invasive Bladder Cancer (Nmibc)

Cited by 2 publications

References 0 publications

Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis

Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis

Bladder cancer: what’s new in 2019—2020

Contact Info

Product

Resources

About